Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 9

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part II, Item 5
Chunk 9
---
ITEM 5.    OTHER INFORMATION

(c) Trading Plans

During the quarter ended December 31, 2024, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated trading plans intended to satisfy Rule 10b5-1(c), except as set forth in the following table:NameTitleAdoption or Termination DatePlan Start DatePlan End DateSharesVesting andSubject toSell-To-Cover (1)OtherSharesBeing Sold(Subject toCertainConditions)James HamiltonChief of Discovery and Translational MedicineTerminated on 10/18/2412/4/202411/28/2025n/a30,000

(1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements. 

29